Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Feature
  • Published:

Turning biodefense dollars into products

Nature Biotechnology volume 25, pages 179–184 (2007)Cite this article

Five years after the US anthrax attacks, and more than two years after BioShield legislation was ratified, a survey reveals that biodefense funding has thus far produced only a handful of products for clinical development.

Access through your institution
Buy or subscribe

This is a preview of subscription content, access via your institution

Access options

Access through your institution

Buy this article

  • Purchase on SpringerLink
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2

References

  1. Trull, M.C., du Laney, T.V. & Dibner, M.D. Biodefense market report: vaccines, therapeutics, and diagnostics for bioterror agents 2006. BioAbility/BioWorld Atlanta, GA (June 2006).

    Google Scholar 

  2. HHS cancels VaxGen's anthrax vaccine contract. (VaxGen, Brisbane, CA, December 19, 2006). http://biz.yahoo.com/prnews/061219/sftu092.html?.v=78

  3. Warrick, J. The secretive fight against bioterror. The Washington Post (July 30, 2006) pA01.

    Google Scholar 

  4. http://www.cdc.gov/ncidod/diseases/hepatitis/a/fact.htm

  5. Trull, M.C., du Laney, T.V. & Dibner, M.D. Biodefense market report: drugs and vaccines for bioterror agents. BioAbility/BioWorld Atlanta, GA (May 2005).

    Google Scholar 

  6. Geisbert, T.W. et al. Postexposure protection of guinea pigs against a lethal Ebola virus challenge is conferred by RNA interference. J. Infect. Dis. 193, 1650–1657 (2006).

    Article  CAS  Google Scholar 

  7. Daddario-DiCaprio, K.M. et al. Postexposure protection against Marburg haemorrhagic fever with recombinant vesicular stomatitis virus vectors in non-human primates: an efficacy assessment. Lancet 367, 1399–1404 (2006).

    Article  Google Scholar 

  8. http://www.alphavax.com/products/bio.aspx

  9. AVI BioPharma awarded $28 million biodefense research contract by Department of Defense/DTRA. (AVI BioPharma, Portland, OR, December 4, 2006). http://www.avibio.com/pr/pr327.html

  10. http://www.bt.cdc.gov/agent/agentlist-category.asp

Download references

Author information

Authors and Affiliations

  1. BioAbility, LLC, PO Box 14569, Research Triangle Park, 27709, North Carolina, USA

    Melanie C Trull, Tracey V du Laney & Mark D Dibner

Authors
  1. Melanie C Trull
    View author publications

    Search author on:PubMed Google Scholar

  2. Tracey V du Laney
    View author publications

    Search author on:PubMed Google Scholar

  3. Mark D Dibner
    View author publications

    Search author on:PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Trull, M., du Laney, T. & Dibner, M. Turning biodefense dollars into products. Nat Biotechnol 25, 179–184 (2007). https://doi.org/10.1038/nbt0207-179

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nbt0207-179

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing